Is Paclitaxel-Eluting Stent Use Justified by an Adequate Risk Profile?
JACC Cardiovasc Interv
.
2021 Mar 22;14(6):702-703.
doi: 10.1016/j.jcin.2021.02.015.
Authors
Bernardo Cortese
1
,
Farhat Fouladvant
2
Affiliations
1
San Carlo Clinic, Milan, Italy; Fondazione Ricerca e Innovazione Cardiovascolare, Milan, Italy. Electronic address: bcortese@gmail.com.
2
San Carlo Clinic, Milan, Italy.
PMID:
33736777
DOI:
10.1016/j.jcin.2021.02.015
No abstract available
Keywords:
DCB; DES; paclitaxel; vessel aneurysm; vessel degeneration.
Publication types
Editorial
Comment
MeSH terms
Coronary Restenosis*
Drug-Eluting Stents*
Humans
Paclitaxel / adverse effects
Stents
Treatment Outcome
Substances
Paclitaxel